Rotavirus A (RV-A) Research Reagents — Antibodies & Recombinant Proteins

Rotavirus A (RV-A) is a double-stranded RNA virus causing severe acute gastroenteritis in infants and young children globally. The virus has a triple-layered capsid structure with outer capsid proteins VP4 and VP7 determining serotype (P and G types). VP6 in the intermediate layer is the group antigen. VP4 (spike protein) and VP7 (glycoprotein) are primary targets for neutralizing antibodies and vaccine development. Rotavirus vaccines have significantly reduced disease burden, and diagnostic and therapeutic antibodies remain important for clinical research and vaccine immunogenicity studies.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Rotavirus A virion structure — VP4, VP6, VP7 capsid proteins

Fig. 1 Rotavirus A structure. VP4 and VP7 are outer capsid proteins mediating cell attachment and entry; VP6 is the intermediate capsid layer and group antigen.

abinScience provides InVivoMAb functional-grade antibodies, monoclonal antibodies, and recombinant antigens for Rotavirus A research. All products manufactured by our parent company AtaGenix Laboratories under ISO 9001 & ISO 13485 quality systems. Contact us for vaccine development and neutralization studies.

Key Research Targets

VP4 (Outer Capsid Spike Protein) — VP4 is the spike protein mediating viral attachment to host cell receptors and determines the P serotype. VP4-specific neutralizing antibodies are highly protective and a major vaccine target. InVivoMAb anti-VP4 antibodies (VK676010, VK676020) support neutralization assays, passive immunization studies, and vaccine potency evaluation. Recombinant VP4 protein (VK676012) serves as an immunogen and ELISA coating antigen.
→ Browse RV-A VP4 products

VP7 (Outer Capsid Glycoprotein) — VP7 is the glycoprotein component of the outer capsid and determines the G serotype. VP7-specific neutralizing antibodies are crucial for vaccine-induced protection and are the basis for serotyping. InVivoMAb anti-VP7 antibody (VK603010) enables in vivo neutralization assays and vaccine immunogenicity assessment. VP7 is essential for understanding rotavirus serotype variation and vaccine strain selection.
→ Browse RV-A VP7 products

VP6 (Intermediate Capsid Layer/Group Antigen) — VP6 is the group antigen defining rotavirus serogroup and is the target for diagnostic assays and serological studies. VP6 is less exposed than VP4 and VP7 but remains immunogenic and is useful for rapid seroprevalence surveys. InVivoMAb anti-VP6 antibody (VK447010) supports group-specific detection and ELISA assay development. Recombinant VP6 proteins (VK021012, VK021022) serve as diagnostic coating antigens and immunogen standards.
→ Browse RV-A VP6 products

Recommended Applications

Serological Diagnosis & Vaccine Development
Rotavirus A VP4, VP7, and VP6 recombinant antigens serve as ELISA coating antigens for rapid serodetection and serotype determination. VP4- and VP7-specific InVivoMAb antibodies quantify neutralizing antibody responses in vaccinated and naturally infected populations, supporting vaccine potency testing and clinical immunogenicity studies.

Neutralization Assays & Functional Studies
InVivoMAb-grade VP4 and VP7 antibodies enable in vitro and in vivo neutralization assays, blocking assays, and passive immunization studies. Monoclonal antibodies (VK524015, VK524025, VK524035, VK524045) provide epitope-specific detection for mechanistic studies and serotype characterization.

References

1. Estes MK, Greenberg HB. Rotaviruses. In: Knipe DM, Howley PM, eds. Fields Virology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 1347-1401.

2. Tate JE, Burton AH, Boschi-Pinto C, et al. 2016 rotavirus strain surveillance report. Vaccine. 2018;36(47):7134-7139.

3. Crawford SE, Estes MK, Ciarlet M. The rotavirus vaccines: safety and efficacy. Curr Opin Infect Dis. 2011;24(6):598-610.

4. Ramani S, Estes MK, Poling LG, et al. Quantity, quality, and duration of breast milk immunoglobulin A antibody response to an oral rotavirus vaccine. Vaccine. 2016;34(27):3100-3107.

All products manufactured by AtaGenix Laboratories under ISO 9001 & ISO 13485 quality systems. Contact us for custom antibody development.